Diosynth Biotechnology signed an agreement with VGX Pharmaceuticals for process development activities and cGMP production of clinical trial material for their biological drug candidate VGX-100 for the treatment of cancer. VGX has developed technology using specific viral proteins that can induce selective apoptosis (programmed cell death) in rapidly dividing cancer cells, leaving normal cells unharmed. VGX-100, a recombinant viral protein, induces tumor cell death through apoptosis in num...